Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Devgen (EBR:DEVG) Gent (Belgium) - Regulatory Release - Transparency declarations from the major shareholders of Devgen NV
Ghent (Belgium) - October 28, 2008, 18:00 CET - Devgen NV (Euronext Brussels: DEVG) announced today that it has received transparency declarations from several major shareholders pursuant to the new transparency legislation (Belgian Act of May 2, 2007) concerning major holdings in issuers whose shares are admitted to trading on a regulated Belgian market.
On September 1, 2008, Devgen NV had 17, 881, 500 shares outstanding. The following shareholders have informed Devgen NV of their holdings as of September 1, 2008:
Shareholder Number of shares % of outstanding shares O.G.B.B. A. van Herk 2,277,266 12.74% B.V. Petercam 1,423,430 7.96% Global Opportunities Capital 1,321,730 7.39% Asset Monsanto Company 1,045,400 5.85% Hermes 833,000 4.66% KBC Asset Management 558,863 3.13%
The above parties made their declarations separately and are acting independently. Information concerning the transparency legislation
Detailed information concerning the transparency legislation can be found in the Extract from the "Guide to the Transparency Legislation CBFA_2008_16 of 8 July 2008" which is available from the website of the Banking, Finance and Insurance Commission (CBFA): www.cbfa.be/eng/gv/ah/circ/pdf/cbfa_2008_16.pdf
For submitting the notifications the CBFA recommends the use of its standard form TR-1 BE, which is also available from the CBFA website: www.cbfa.be/eng/gv/ah/circ/pdf/TR-1BE.xls
The notifications should be transmitted to both Devgen and the CBFA. The CBFA recommends transmitting the notifications first electronically, to the e-mail address trp.fin@cbfa.be, and subsequently - for reasons of legal certainty - by fax to number + 32 2 220 59 12.
It is recommended to transmit notifications to Devgen NV by email to the attention of:
Devgen is a public agricultural biotech and seed company focused on developing and commercializing:
* biotech traits and hybrid seeds to meet the growing needs for high yielding, high quality hybrid rice, sorghum, millet and sunflower of the Indian and other south-east Asian markets; * a novel generation of biotech products to protect a wide spectrum of crops incurred from pests; to render crops more tolerant against stress factors such as drought and salty soils and to decrease the need for fertilizer use by optimizing nitrogen uptake; * a new generation of agrochemical products to protect crops from damage inflicted by plant parasitic nematodes.
Incorporated in 1997, Devgen has offices in Ghent (Belgium), Singapore, Hyderabad (India) and Delaware (US) and employs more than 200 people worldwide. Devgen is listed on Euronext Brussels (ticker: DEVG) since June 2005.
This press release may contain forward-looking statements containing the words "anticipates", "expects" , "intends", "plans", "estimates", "may" and "continues" as well as similar expressions. Such forward looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, performance or achievements of Devgen to be materially different from any future results or achievements expressed or implied by such forward-looking statements. These forward looking statements speak only as of the date of publication of this document. Devgen disclaims any obligation to update such forward looking statements in this document to reflect any change in its expectations, conditions or circumstances on which such statement is based, unless required by law or regulation.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
